311 related articles for article (PubMed ID: 29380516)
21. Dabrafenib and Trametinib Treatment in Patients With Locally Advanced or Metastatic BRAF V600-Mutant Anaplastic Thyroid Cancer.
Subbiah V; Kreitman RJ; Wainberg ZA; Cho JY; Schellens JHM; Soria JC; Wen PY; Zielinski C; Cabanillas ME; Urbanowitz G; Mookerjee B; Wang D; Rangwala F; Keam B
J Clin Oncol; 2018 Jan; 36(1):7-13. PubMed ID: 29072975
[TBL] [Abstract][Full Text] [Related]
22. Successful (neo)adjuvant BRAF-targeted therapy in a patient with locally advanced BRAF V600E mutant melanoma.
Seremet T; Lienard D; Suppa M; Trepant AL; Rorive S; Woff E; Cuylits N; Jansen Y; Schreuer M; Del Marmol V; Neyns B
Melanoma Res; 2015 Apr; 25(2):180-3. PubMed ID: 25643238
[TBL] [Abstract][Full Text] [Related]
23. Vemurafenib and cobimetinib overcome resistance to vemurafenib in
Touat M; Gratieux J; Condette Auliac S; Sejean K; Aldea S; Savatovsky J; Perkins G; Blons H; Ligon KL; Idbaih A; Hollebecque A; Gimenez-Roqueplo AP; Laurent-Puig P; Sanson M; Villa C; Di Stefano AL
Neurology; 2018 Sep; 91(11):523-525. PubMed ID: 30120137
[No Abstract] [Full Text] [Related]
24. Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic Melanoma.
Robert C; Grob JJ; Stroyakovskiy D; Karaszewska B; Hauschild A; Levchenko E; Chiarion Sileni V; Schachter J; Garbe C; Bondarenko I; Gogas H; Mandalá M; Haanen JBAG; Lebbé C; Mackiewicz A; Rutkowski P; Nathan PD; Ribas A; Davies MA; Flaherty KT; Burgess P; Tan M; Gasal E; Voi M; Schadendorf D; Long GV
N Engl J Med; 2019 Aug; 381(7):626-636. PubMed ID: 31166680
[TBL] [Abstract][Full Text] [Related]
25. Dabrafenib plus trametinib in patients with BRAF
Davies MA; Saiag P; Robert C; Grob JJ; Flaherty KT; Arance A; Chiarion-Sileni V; Thomas L; Lesimple T; Mortier L; Moschos SJ; Hogg D; Márquez-Rodas I; Del Vecchio M; Lebbé C; Meyer N; Zhang Y; Huang Y; Mookerjee B; Long GV
Lancet Oncol; 2017 Jul; 18(7):863-873. PubMed ID: 28592387
[TBL] [Abstract][Full Text] [Related]
26. Overcoming acquired BRAF inhibitor resistance in melanoma via targeted inhibition of Hsp90 with ganetespib.
Acquaviva J; Smith DL; Jimenez JP; Zhang C; Sequeira M; He S; Sang J; Bates RC; Proia DA
Mol Cancer Ther; 2014 Feb; 13(2):353-63. PubMed ID: 24398428
[TBL] [Abstract][Full Text] [Related]
27. Partial response to dabrafenib and trametinib in relapsed BRAF V600E-Mutated multiple myeloma and possible mechanisms of resistance.
Ernst T; Aebi S; Zander A; Zander T
BMJ Case Rep; 2022 Apr; 15(4):. PubMed ID: 35396243
[TBL] [Abstract][Full Text] [Related]
28. Molecular pathways: adaptive kinome reprogramming in response to targeted inhibition of the BRAF-MEK-ERK pathway in cancer.
Johnson GL; Stuhlmiller TJ; Angus SP; Zawistowski JS; Graves LM
Clin Cancer Res; 2014 May; 20(10):2516-22. PubMed ID: 24664307
[TBL] [Abstract][Full Text] [Related]
29. Dabrafenib treatment in a patient with BRAF V600E ganglioglioma: circulating exosome-derived cancer RNA supports treatment choice and clinical monitoring.
Pasqualetti F; Restante G; Gonnelli A; Rofi E; Molinari A; Crucitta S; Paiar F; Rudà R; Danesi R; Soffietti R; Del Re M
Neuro Oncol; 2019 Dec; 21(12):1610-1611. PubMed ID: 31504796
[No Abstract] [Full Text] [Related]
30.
Middleton G; Yang Y; Campbell CD; André T; Atreya CE; Schellens JHM; Yoshino T; Bendell JC; Hollebecque A; McRee AJ; Siena S; Gordon MS; Tabernero J; Yaeger R; O'Dwyer PJ; De Vos F; Van Cutsem E; Millholland JM; Brase JC; Rangwala F; Gasal E; Corcoran RB
Clin Cancer Res; 2020 Jun; 26(11):2466-2476. PubMed ID: 32047001
[TBL] [Abstract][Full Text] [Related]
31. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer.
Joshi M; Rice SJ; Liu X; Miller B; Belani CP
PLoS One; 2015; 10(2):e0118210. PubMed ID: 25706985
[TBL] [Abstract][Full Text] [Related]
32. Dabrafenib and Trametinib in Patients With Tumors With
Salama AKS; Li S; Macrae ER; Park JI; Mitchell EP; Zwiebel JA; Chen HX; Gray RJ; McShane LM; Rubinstein LV; Patton D; Williams PM; Hamilton SR; Armstrong DK; Conley BA; Arteaga CL; Harris LN; O'Dwyer PJ; Chen AP; Flaherty KT
J Clin Oncol; 2020 Nov; 38(33):3895-3904. PubMed ID: 32758030
[TBL] [Abstract][Full Text] [Related]
33. Combined BRAF and MEK inhibition for the treatment of BRAF-mutated metastatic melanoma.
Queirolo P; Picasso V; Spagnolo F
Cancer Treat Rev; 2015 Jun; 41(6):519-26. PubMed ID: 25944484
[TBL] [Abstract][Full Text] [Related]
34. BRAF inhibition for advanced locoregional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
Sloot S; Zager JS; Kudchadkar RR; Messina JL; Benedict JJ; Gonzalez RJ; DeConti R; Turner LM; McCardle T; Smalley KS; Weber JS; Sondak VK; Gibney GT
Melanoma Res; 2016 Feb; 26(1):83-7. PubMed ID: 26731560
[TBL] [Abstract][Full Text] [Related]
35. Dabrafenib; preclinical characterization, increased efficacy when combined with trametinib, while BRAF/MEK tool combination reduced skin lesions.
King AJ; Arnone MR; Bleam MR; Moss KG; Yang J; Fedorowicz KE; Smitheman KN; Erhardt JA; Hughes-Earle A; Kane-Carson LS; Sinnamon RH; Qi H; Rheault TR; Uehling DE; Laquerre SG
PLoS One; 2013; 8(7):e67583. PubMed ID: 23844038
[TBL] [Abstract][Full Text] [Related]
36. Dabrafenib plus Trametinib: a Review in Advanced Melanoma with a BRAF (V600) Mutation.
Dhillon S
Target Oncol; 2016 Jun; 11(3):417-28. PubMed ID: 27246822
[TBL] [Abstract][Full Text] [Related]
37. Acquired BRAF V600E Mutation Mediated Resistance to Osimertinib and Responded to Osimertinib, Dabrafenib, and Trametinib Combination Therapy.
Huang Y; Gan J; Guo K; Deng Y; Fang W
J Thorac Oncol; 2019 Oct; 14(10):e236-e237. PubMed ID: 31558239
[No Abstract] [Full Text] [Related]
38. Ipilimumab, vemurafenib, dabrafenib, and trametinib: synergistic competitors in the clinical management of BRAF mutant malignant melanoma.
Luke JJ; Hodi FS
Oncologist; 2013 Jun; 18(6):717-25. PubMed ID: 23709751
[TBL] [Abstract][Full Text] [Related]
39. Adjuvant dabrafenib plus trametinib versus placebo in patients with resected, BRAF
Dummer R; Brase JC; Garrett J; Campbell CD; Gasal E; Squires M; Gusenleitner D; Santinami M; Atkinson V; Mandalà M; Chiarion-Sileni V; Flaherty K; Larkin J; Robert C; Kefford R; Kirkwood JM; Hauschild A; Schadendorf D; Long GV
Lancet Oncol; 2020 Mar; 21(3):358-372. PubMed ID: 32007138
[TBL] [Abstract][Full Text] [Related]
40. Combinations of BRAF, MEK, and PI3K/mTOR inhibitors overcome acquired resistance to the BRAF inhibitor GSK2118436 dabrafenib, mediated by NRAS or MEK mutations.
Greger JG; Eastman SD; Zhang V; Bleam MR; Hughes AM; Smitheman KN; Dickerson SH; Laquerre SG; Liu L; Gilmer TM
Mol Cancer Ther; 2012 Apr; 11(4):909-20. PubMed ID: 22389471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]